树突状细胞在多发性骨髓瘤免疫治疗中的应用进展

The Development of Dendritic Cells in Multiple Myeloma Immunotherapy

多发性骨髓瘤(multiple myeloma,MM)患者在常规治疗达完全缓解后,体内仍会存在微小残留病变(minimal residual disease,MRD),而成为复发的根源,此时依靠机体有效的抗肿瘤免疫反应是消除MRD的一个有效的方法。树突状细胞(dendritic cell,DC)是目前功能最强大、唯一能激活初始型T细胞的抗原递呈细胞(antigen presenting cell,APC),能有效的把MM的肿瘤抗原呈递给T细胞,产生特异性CTL而达到杀灭肿瘤细胞的目的。对DC在MM免疫治疗中的基础研究和临床应用进展的研究很有意义。

The minimal residual disease is the reason of relapse in the multiple myeloma （MM） patients after complete remission by routine treatment. In this case, anti-tumor immune responses is an effective way to eradicate the minimal residual disease. So far it is known that the dendritic cells are the most potent antigen presenting cells and the only ones capable of sensitizing na＇l＇ve and unprimed T cells. They can effectively present the antigen of MM to T cells which can be induced to CTLs which are capable of killing tumor cells. The article reviews the basic studies and clinical applications of dendritic cells in multiple myeloma immunotherapy.